0.3423
price up icon1.85%   0.0076
 
loading
Fibrogen Inc stock is traded at $0.3423, with a volume of 752.52K. It is up +1.85% in the last 24 hours and down -12.92% over the past month. FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
See More
Previous Close:
$0.3347
Open:
$0.3526
24h Volume:
752.52K
Relative Volume:
0.62
Market Cap:
$33.58M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-0.101
EPS:
-3.39
Net Cash Flow:
$-317.54M
1W Performance:
+0.68%
1M Performance:
-12.92%
6M Performance:
-71.59%
1Y Performance:
-40.25%
1-Day Range:
Value
$0.33
$0.3526
1-Week Range:
Value
$0.18
$0.4245
52-Week Range:
Value
$0.18
$2.93

Fibrogen Inc Stock (FGEN) Company Profile

Name
Name
Fibrogen Inc
Name
Phone
415-978-1200
Name
Address
350 BAY STREET, SAN FRANCISCO, CA
Name
Employee
486
Name
Twitter
@FibroGenInc
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
FGEN's Discussions on Twitter

Compare FGEN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
FGEN 0.3423 33.58M 147.75M -284.23M -317.54M -3.39
VRTX 467.20 119.83B 10.63B -479.80M -1.35B 13.33
REGN 760.66 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.96 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.32 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.33 24.08B 3.30B -501.07M 1.03B 11.54

Fibrogen Inc Stock (FGEN) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-08-23 Downgrade BofA Securities Neutral → Underperform
Jun-26-23 Downgrade BofA Securities Buy → Neutral
Jun-26-23 Downgrade Raymond James Outperform → Mkt Perform
Jun-26-23 Downgrade Stifel Buy → Hold
Jun-26-23 Downgrade William Blair Outperform → Mkt Perform
Jun-02-23 Upgrade Stifel Hold → Buy
Jan-31-23 Upgrade William Blair Mkt Perform → Outperform
Jan-26-23 Upgrade Raymond James Mkt Perform → Outperform
Jan-05-23 Upgrade BofA Securities Neutral → Buy
Sep-22-21 Downgrade Goldman Neutral → Sell
Aug-20-21 Upgrade Raymond James Underperform → Mkt Perform
Jul-16-21 Downgrade BofA Securities Buy → Neutral
Jul-16-21 Downgrade Stifel Buy → Hold
Apr-07-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-07-21 Downgrade Mizuho Buy → Neutral
Mar-31-21 Upgrade BofA Securities Neutral → Buy
Mar-02-21 Downgrade Jefferies Buy → Hold
Feb-01-21 Initiated H.C. Wainwright Buy
Oct-26-20 Initiated Raymond James Underperform
Jul-10-20 Resumed Stifel Buy
May-01-20 Initiated Cowen Market Perform
Apr-27-20 Initiated BofA/Merrill Neutral
May-29-19 Resumed Goldman Neutral
May-10-19 Downgrade William Blair Outperform → Mkt Perform
Apr-12-19 Initiated Piper Jaffray Neutral
Feb-11-19 Resumed Stifel Buy
Dec-19-18 Upgrade Citigroup Neutral → Buy
Aug-08-17 Reiterated Leerink Partners Outperform
Aug-08-17 Reiterated Stifel Buy
Jul-21-17 Downgrade Goldman Buy → Neutral
Jul-11-17 Initiated Jefferies Buy
Feb-11-16 Upgrade Credit Suisse Neutral → Outperform
Jan-21-16 Initiated Credit Suisse Neutral
Dec-04-15 Initiated Citigroup Buy
Sep-23-15 Initiated Lake Street Hold
Jul-29-15 Initiated Citigroup Buy
Jul-20-15 Upgrade Goldman Neutral → Buy
Dec-09-14 Initiated Stifel Buy
View All

Fibrogen Inc Stock (FGEN) Latest News

pulisher
Nov 16, 2024

StockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN) - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

ARMISTICE CAPITAL, LLC Reduces Stake in FibroGen Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

FibroGen Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 15, 2024
pulisher
Nov 13, 2024

FGEN stock touches 52-week low at $0.19 amid market challenges - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

FibroGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

FibroGen, Inc. (NASDAQ:FGEN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: FibroGen reports strong Q3 sales, advances in oncology pipeline - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

FibroGen: Q3 Earnings Snapshot - mySA

Nov 13, 2024
pulisher
Nov 13, 2024

FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 13, 2024
pulisher
Nov 13, 2024

FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions By GuruFocus - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions - Yahoo Finance

Nov 13, 2024
pulisher
Nov 12, 2024

FibroGen Reports Strong Q3 Growth and Future Plans - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

FibroGen Inc earnings beat by $0.14, revenue topped estimates - Investing.com Australia

Nov 12, 2024
pulisher
Nov 12, 2024

FibroGen Inc (FGEN) Q3 2024 Earnings: Revenue Surges to $46.3M, EPS at $(0.17), Exceeding Estimates - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

FibroGen Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

FibroGen Q3 Revenue Surges 15% as China Sales Soar; Narrows Net Loss by 73% | FGEN Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 07, 2024

FibroGen Inc (FGEN) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register

Nov 07, 2024
pulisher
Nov 04, 2024

FibroGen to Report Third Quarter 2024 Financial Results - GlobeNewswire

Nov 04, 2024
pulisher
Oct 31, 2024

Metrics That Matter About FibroGen Inc (NASDAQ: FGEN) - Stocks Register

Oct 31, 2024
pulisher
Oct 29, 2024

FGEN stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia

Oct 29, 2024
pulisher
Oct 29, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding - Simply Wall St

Oct 29, 2024
pulisher
Oct 29, 2024

FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com - Defense World

Oct 29, 2024
pulisher
Oct 28, 2024

FGEN stock touches 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 21, 2024

FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com - Defense World

Oct 21, 2024
pulisher
Oct 16, 2024

The growth track for FibroGen Inc (FGEN) has changed recently - SETE News

Oct 16, 2024
pulisher
Oct 15, 2024

Should investors be concerned about FibroGen Inc (FGEN)? - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Cubist Systematic Strategies LLC Has $256,000 Stock Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Oct 15, 2024
pulisher
Oct 14, 2024

Market Watch: FibroGen Inc (FGEN)’s Noteworthy Gain, Closing at 0.36 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

FibroGen Hits New 52-week High, What's Fuelling The Stock? - RTTNews

Oct 14, 2024
pulisher
Oct 14, 2024

Pulmonary Fibrosis Drug Market Size & Analysis By 2024 -2034 -Boehringer Ingelheim, Roche, FibroGen, Inc., Merck & Co., – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 12, 2024

Sei Investments Co. Purchases 41,442 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World

Oct 12, 2024
pulisher
Oct 12, 2024

Financial Review: FibroGen (NASDAQ:FGEN) and Oncotelic Therapeutics (OTCMKTS:OTLC) - Defense World

Oct 12, 2024
pulisher
Oct 11, 2024

FibroGen's US$6.2m Market Cap Fall Books Insider Losses - Simply Wall St

Oct 11, 2024
pulisher
Oct 10, 2024

FibroGen Inc [FGEN] Chief Medical Officer makes an insider acquire of 22,123 shares worth 25,884. - Knox Daily

Oct 10, 2024
pulisher
Oct 09, 2024

FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Investors in cash trouble should check out FibroGen Inc (FGEN) - SETE News

Oct 09, 2024
pulisher
Oct 08, 2024

FGEN stock touches 52-week low at $0.33 amid market challenges By Investing.com - Investing.com South Africa

Oct 08, 2024
pulisher
Oct 08, 2024

FGEN stock touches 52-week low at $0.33 amid market challenges - Investing.com Australia

Oct 08, 2024
pulisher
Oct 08, 2024

A year in review: FibroGen Inc (FGEN)’s performance in the last year - US Post News

Oct 08, 2024
pulisher
Oct 07, 2024

Trading Day Triumph: FibroGen Inc (FGEN) Ends at 0.37, a -8.07 Surge/Plunge - The Dwinnex

Oct 07, 2024
pulisher
Oct 07, 2024

FibroGen Inc Inc. (FGEN) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle

Oct 07, 2024
pulisher
Oct 07, 2024

Investing in FibroGen Inc (FGEN): What You Must Know - Knox Daily

Oct 07, 2024
pulisher
Oct 05, 2024

StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN) - Defense World

Oct 05, 2024
pulisher
Oct 04, 2024

FibroGen will pay $10M to exit HQ lease in SF’s Mission Bay - The Real Deal

Oct 04, 2024
pulisher
Oct 03, 2024

FibroGen Suit Alleging Disclosure Failures Tossed In Del. - Law360

Oct 03, 2024

Fibrogen Inc Stock (FGEN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Fibrogen Inc Stock (FGEN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Wettig Thane
CEO
Mar 07 '24
Buy
1.91
50,000
95,470
470,178
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.04
price down icon 0.87%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):